Enterprise Value

3.231B

Cash

565.7M

Avg Qtr Burn

-106.6M

Short % of Float

14.44%

Insider Ownership

0.89%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Omecamtiv Mecarbil (cardiac myosin activator) Details
Pancreatic cancer, Heart disease, Heart failure

NDA

FDA meeting

Aficamten (CK-274) (cardiac myosin inhibitor) Details
Heart disease, Hypertrophic cardiomyopathies

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 1

Data readout

CK-3828136(CK-136)(cardiac troponin activator) Details
Heart disease, Heart failure, Epilepsy

Phase 1

Data readout

Failed

Discontinued